

UCSF

UC San Francisco Previously Published Works

Title

Low Prevalence of Interferon α Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID.

Permalink

<https://escholarship.org/uc/item/1s37n1b2>

Journal

The Journal of infectious diseases, 227(2)

ISSN

0022-1899

Authors

Peluso, Michael J
Mitchell, Anthea
Wang, Chung Yu
[et al.](#)

Publication Date

2023

DOI

10.1093/infdis/jiac372

Peer reviewed

1 **Low Prevalence of Interferon- α Autoantibodies in People Experiencing Long COVID**

2 **Symptoms**

3 Michael J. Peluso,¹ Anthea Mitchell,² Chung Yu Wang,² Saki Takahashi,¹ Rebecca Hoh,¹ Viva
4 Tai,¹ Matthew S. Durstenfeld,³ Priscilla Y. Hsue,³ J. Daniel Kelly,⁴ Jeffrey N. Martin,⁴ Michael R.
5 Wilson,⁵ Bryan Greenhouse,¹ Steven G. Deeks,¹ Joseph L. DeRisi,² Timothy J. Henrich⁶

6 1 Division of HIV, Infectious Diseases, and Global Medicine, University of California, San
7 Francisco, San Francisco, CA, USA

8 2 Chan Zuckerberg Biohub, San Francisco, CA, USA

9 3 Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA

10 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San
11 Francisco, CA, USA

12 5 Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

13 6 Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA,
14 USA

15 Corresponding Author: Michael J. Peluso
16 Division of HIV, Infectious Diseases, and Global Medicine
17 1001 Potrero Ave, Bldg 80
18 San Francisco, CA 94110, USA
19 michael.peluso@ucsf.edu
20 415-476-4082 ext 119
21

22 Short Title: Anti-interferon autoantibodies in Long COVID

23

1 **ABSTRACT**

2 Interferon (IFN)-specific autoantibodies have been implicated in severe COVID-19 and have
3 been proposed as a potential driver of the persistent symptoms characterizing Long COVID, a
4 type of post-acute sequelae of SARS-CoV-2 infection (PASC). We report that only two of 215
5 SARS-CoV-2 convalescent participants tested over 394 timepoints, including 121 people
6 experiencing Long COVID symptoms, had detectable IFN- α 2 antibodies. Both had been
7 hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN
8 antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to Long
9 COVID symptoms in the post-acute phase of the infection.

10

11 Keywords: COVID-19, SARS-CoV-2, post-acute sequelae of SARS-CoV-2 infection, post-
12 COVID conditions, Long COVID, autoimmunity, interferon autoantibodies

13

1 INTRODUCTION

2 Post-acute sequelae of SARS-CoV-2 infection (PASC) or post-COVID conditions include
3 incident medical diagnoses such as diabetes, cardiovascular events, stroke, and mental health
4 issues, as well as chronic or persistent physical symptoms not attributable to another cause.
5 Often referred to as “Long Covid,” these symptoms represent one type of PASC and can lead to
6 marked morbidity and functional limitations in the months following acute infection [1]. The
7 mechanisms underlying Long COVID are unknown and elucidating its cause has become a
8 major research priority [2].

9 Interferons (IFNs) play vital roles in innate antiviral immune responses, and SARS-CoV-2
10 infection has been shown to hamper type I and type III IFN responses [3]. Furthermore, inborn
11 errors in Type 1 IFN pathways and autoantibodies that neutralize type I IFNs have been
12 identified in some individuals with COVID-19 who require a high level of care during acute
13 infection, but not in those with milder initial disease [4-9]. For example, in one study early in the
14 pandemic, over 10% of patients with severe COVID-19 exhibited neutralizing autoantibodies to
15 type 1 IFNs early in the disease course [4]. A more recent study of blood donors previously
16 hospitalized with COVID-19 showed that 4/116 (3%) had detectable anti-IFN- α 2 antibodies a
17 minimum of 14-28 days following resolution of symptoms [10], in the early post-acute period. It
18 has been argued that disruption of IFN pathways could be a contributor to severe illness in a
19 significant proportion of cases of COVID-19 [9].

20 The presence of IFN-specific autoantibodies has also been proposed as a potential driver of
21 PASC, including Long COVID [11]. This hypothesis gained much attention following a
22 provocative study which demonstrated an association between detection of IFN- α 2-specific
23 autoantibodies and the presence of pulmonary symptoms at timepoints during acute SARS-
24 CoV-2 infection and 2-3 months following the initial presentation [12]. The authors argued that
25 these antibodies might be uniquely associated with respiratory Long COVID symptoms. This

1 observation has not yet been confirmed in other post-acute cohorts, and the prevalence of IFN-
2 specific autoantibody responses and their association with post-acute symptoms over longer
3 periods of time consistent with current case definitions of Long COVID is not known. Further in-
4 depth study of specific autoimmune mechanisms is critical given the broad therapeutic potential
5 of targeting various autoreactive immune responses. For this reason, we measured the
6 presence of anti-IFN- α 2 autoantibodies in plasma from 215 SARS-CoV-2 convalescent
7 participants over 394 unique time points in a diverse post-acute COVID-19 cohort, including 121
8 individuals with a variety of mild to severe Long COVID symptoms.

10 **METHODS**

11 **Ethics.** The study was approved by the UCSF institutional review board. All participants
12 provided written informed consent.

13 **Study Cohort and Sample Acquisition.** Samples and in-depth demographic, symptom and
14 clinical data were obtained from the Long-term Impact of Infection with Novel Coronavirus
15 (LIINC) study (NCT04362150) which includes diverse participants with nucleic acid-confirmed
16 SARS-CoV-2 infection, many of whom experience post-COVID conditions such as Long COVID.
17 The cohort procedures, including recruitment, approaches to measurement, and follow-up, have
18 been described in detail elsewhere [13]. Briefly, individuals with a history of nucleic acid-
19 confirmed SARS-CoV-2 infection were enrolled and completed in-person visits at our research
20 center in San Francisco; most were sampled approximately monthly from enrollment until 4
21 months following infection, and then quarterly thereafter. Plasma was obtained by centrifugation
22 of EDTA whole blood samples. Samples were collected from April 21, 2020 through June 29,
23 2021. These samples represented all individuals in the cohort who enrolled prior to receiving a

1 SARS-CoV-2 vaccine. The median number of samples studied per participant was 2 (IQR: 1.5-
2 2).

3 **Long COVID Assessment.** We assessed for the presence of Long COVID cross-sectionally at
4 each visit. For this study, we defined Long COVID as the presence of COVID-attributed
5 symptoms at a visit occurring 60 or more days from initial COVID-19 symptom onset.

6 **IFN-specific autoantibody measurement.** Anti-IFN- α 2 antibodies were measured using a
7 previously published immunoprecipitation method [8, 10]. Briefly, a sequence-verified plasmid
8 containing full-length IFNA2 cDNA sequence with a Flag-Myc tag (Origene#RC221091) was
9 used as template in T7-promoter-based in vitro transcription/translation reactions (Promega,
10 Madison, WI: #L1170) using [³⁵S]-methionine (PerkinELmer, Waltham, MA; #NEG709A).
11 Protein was column-purified using Nap-5 columns (GE Healthcare, Chicago, IL; #17-0853-01),
12 incubated with 2.5- μ l plasma or 1- μ l anti-myc positive control antibody (CellSignal, Danvers,
13 MA; #2272), and immunoprecipitated with Sephadex protein A/G beads (Sigma Aldrich, St.
14 Louis, MO; #GE17-5280-02 and #GE17-0618-05, 4:1 ratio) in 96-well polyvinylidene difluoride
15 filtration plates (Corning, Corning, NY; #EK-680860). The radioactive counts (cpm) of
16 immunoprecipitated protein were quantified using a Microbeta Trilux liquid scintillation plate
17 reader (Perkin Elmer). Antibody index for each sample was calculated as follows: (sample cpm
18 value – mean blank cpm value)/(positive control antibody cpm value – mean blank cpm value).
19 Positive signal was defined as greater than 4 standard deviations above the mean of pre-
20 COVID-19 blood bank non-inflammatory controls as previously reported [10]. APS1 samples
21 were used as positive controls.

22

23

1 RESULTS

2 As shown in **Table 1**, 215 unique participants were assessed and biospecimens collected at
3 394 timepoints from 0.5 to 14.7 months following symptom onset (median 94 days, IQR 52-124
4 days). Ninety (42%) participants were female and 48 (22%) had been hospitalized during the
5 acute phase of COVID-19; of those hospitalized, 16 (40%) had been in the ICU and 6 (15%)
6 required mechanical ventilation. Of the 394 participant-timepoints, 272 timepoints representing
7 185 unique individuals occurred 60 or more days following COVID-19 symptom onset, allowing
8 for assessment of the presence of Long COVID at the visit. 121 unique participants at 182
9 different timepoints met Long COVID criteria, defined as at least one COVID-19-attributed
10 symptom at a timepoint 60 days or more from initial symptom onset. The cohort experiencing
11 Long COVID was highly symptomatic. Among timepoints in which participants endorsed Long
12 COVID symptoms, the median number of symptoms at any timepoint was 5 (IQR 2-8). Sixty-
13 four unique participants at 91 different time points endorsed 5 or more symptoms; 22 unique
14 individuals at 29 different time points endorsed 10 or more symptoms.

15
16 IFN- α 2-specific autoantibodies were detected in only two of 215 participants across all sample
17 timepoints. Both were Latino males in their late 40s to early 50s with pre-existing diabetes and
18 hypertension who experienced severe COVID-19 requiring hospitalization during the acute
19 phase of infection (**Figure 1; Table 1**). The first participant had detectable anti-IFN abs at 87
20 and 115 days following acute infection. He had initially presented in Spring 2020 after suffering
21 pulseless electrical activity (PEA) arrest requiring resuscitation and mechanical ventilation 10
22 days after onset of COVID-19 symptoms. Following hospitalization, he experienced intermittent
23 viral shedding detected on clinical nucleic acid amplification testing for approximately 6 months
24 and reported persistent anosmia and an intermittent neuropathic pain syndrome for at least 18
25 months. The second participant had detectable anti-IFN antibodies at 41 and 90 days after

1 acute infection and was hospitalized in early 2021 requiring supplemental oxygen. He
2 subsequently developed Long COVID with fatigue, shortness of breath, concentration
3 difficulties, headache, vision changes and peripheral neuropathy that have persisted for at least
4 12 months. In both cases, persistent symptoms were attributed to Long COVID, although we
5 note that both individuals experienced complex hospital courses which could have resulted in
6 post-hospitalization syndromes (e.g., post-intensive care unit syndrome), which can be difficult
7 to disentangle from Long COVID.

8 Whereas these two individuals with IFN- α 2-specific autoantibodies both went on to experience
9 post-acute symptoms, the large majority (99%) of our cohort had no detectable anti-IFN
10 antibodies at any time point. IFN- α 2-specific autoantibodies were not identified in any
11 individuals who were managed as outpatients for COVID-19. Aside from the two persons
12 described above, IFN- α 2-specific autoantibodies were not identified in any other individuals who
13 went on to experience moderate-to-severe Long COVID symptoms persisting for up to 2 years.

14 **DISCUSSION**

15 We found that anti-IFN- α 2 antibodies, which have been identified as a contributor to severe
16 acute COVID-19 and proposed as a contributor to post-acute Long COVID symptoms, were
17 uncommon in our post-acute COVID-19 cohort, including among individuals with Long COVID.

18 Our findings of anti-IFN antibodies limited to two individuals previously hospitalized for COVID-
19 19 are consistent with the published literature [9]. To date, most assessments of anti-IFN
20 antibodies have been conducted during the acute phase of COVID-19. During the acute phase,
21 anti-IFN- α 2 antibodies have been observed in a sizeable proportion of SARS-CoV-2-infected
22 patients hospitalized with severe COVID-19, but such antibodies are not common in those with
23 mild illness [4-9]. For example, it was previously reported that IFN- α 2-specific antibodies are
24 detected during acute SARS-CoV-2 infection in those that require critical care for severe illness

1 (>10%) [4]. In most cases, the autoantibodies are thought to pre-date the illness. These
2 antibodies are uncommon in healthy controls (approximately 0.3%) [8].

3 While severity of illness is thought to be a predictor of Long COVID, most individuals with this
4 condition did not require hospitalization during the acute phase of COVID-19 [1]. The
5 assessment of anti-IFN antibodies in the post-acute phase has been more limited, but their
6 presence has been proposed as a potential driver of Long COVID symptoms [11]. In one PASC
7 study, correlations were noted between the presence of these antibodies and pulmonary
8 symptoms (e.g., cough and sputum production) in a cohort comprised mostly of previously
9 hospitalized individuals 2-3 months following symptom onset [12]. The majority of our post-acute
10 participants (~75%) had not been hospitalized, and none of these individuals exhibited anti-IFN
11 autoantibodies despite the presence of Long COVID symptoms. Furthermore, many studies
12 have reported that persistent symptoms more prevalent in females [1], while IFN-specific
13 autoantibodies are more commonly identified in males.

14 Type 1 IFN responses play a dual role in viral infection; while they exert antiviral activity during
15 the acute phase of many infections, paradoxically they can contribute to the establishment of
16 chronic infection through their immunoregulatory roles [14]. The growing indirect evidence in
17 Long COVID including the nature of symptoms, female preponderance, and upregulation of
18 other cytokines [2], argues that excess signaling rather than inhibition might be more likely to
19 contribute to this condition. Taken in context, our data suggest that while anti-IFN antibodies
20 may contribute to severe SARS-CoV-2 infection, the presence of these antibodies is unlikely to
21 be a primary driver of Long COVID symptoms, in particular those who were not hospitalized
22 during the acute phase of COVID-19.

23 These data do not, however, negate the hypothesis that other autoreactive antibodies that
24 develop during SARS-CoV-2 infection may target portions of the human proteome leading to
25 tissue damage and the pathophysiological development of Long COVID. For example, one

1 study demonstrated the presence of autoantibodies targeting G-protein coupled receptors
2 involved in cardiovascular and neurologic function in patients recovering from COVID-19 [15].
3 Overall, there are many challenges with studying etiologies of Long COVID given the
4 heterogenous nature of the condition and inconsistent definitions used to describe the
5 syndrome. This further emphasizes the need for larger mechanistic studies in precisely defined
6 clinical cohorts.

7 **Acknowledgments.** We are grateful to the Long-term Impact of Infection with Novel
8 Coronavirus (LIINC) study participants and to the clinical staff who provided care to these
9 individuals during their acute illness period and during their recovery.

10 **Financial support.** This work was supported by the National Institute of Allergy and Infectious
11 Diseases, National Institutes of Health (grant number 3R01AI141003–03S1 to T. J. H.). JD, AM,
12 and CW were supported by the Chan Zuckerberg Biohub.

13 **Potential conflicts of interest.** T. J. H. reports grants from Merck and Co., Gilead
14 Biosciences, and Bristol-Myers Squibb, outside the submitted work. T. J. H. has provided
15 consulting for Roche. S. G. D. reports grants and/or personal fees from Gilead Sciences, Merck
16 & Co., ViiV, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences, outside the submitted
17 work. JD reports paid compensation for consulting for the Public Health Company, Inc., and
18 Allen & Co.

19

1 REFERENCES

- 2 1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* **2021**; 27(4):
3 601-15.
- 4 2. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends Immunol*
5 **2022**; 43(4): 268-70.
- 6 3. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19.
7 *Science* **2022**; 375(6585): 1122-7.
- 8 4. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-
9 threatening COVID-19. *Science* **2020**; 370(6515).
- 10 5. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4%
11 of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. *Sci*
12 *Immunol* **2021**; 6(62).
- 13 6. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-
14 threatening COVID-19. *Science* **2020**; 370(6515).
- 15 7. Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. *Sci*
16 *Immunol* **2022**; 7(67): eabm5505.
- 17 8. van der Wijst MGP, Vazquez SE, Hartoularos GC, et al. Type I interferon autoantibodies are
18 associated with systemic immune alterations in patients with COVID-19. *Sci Transl Med* **2021**;
19 13(612): eabh2624.
- 20 9. Zhang Q, Bastard P, Effort CHG, Cobat A, Casanova JL. Human genetic and immunological
21 determinants of critical COVID-19 pneumonia. *Nature* **2022**; 603(7902): 587-98.
- 22 10. Vazquez SE, Bastard P, Kelly K, et al. Neutralizing Autoantibodies to Type I Interferons in COVID-
23 19 Convalescent Donor Plasma. *J Clin Immunol* **2021**; 41(6): 1169-71.
- 24 11. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview
25 of Biological Factors That May Contribute to Persistent Symptoms. *Front Microbiol* **2021**; 12:
26 698169.
- 27 12. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae.
28 *Cell* **2022**; 185(5): 881-95 e20.
- 29 13. Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms
30 and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches
31 for Measurement. *Open Forum Infect Dis* **2022**; 9(2): ofab640.
- 32 14. Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent
33 SIV infection and slow disease progression. *Nature* **2014**; 511(7511): 601-5.
- 34 15. Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled
35 receptors in patients with persistent Long-COVID-19 symptoms. *J Transl Autoimmun* **2021**; 4:
36 100100.

37

38

1 **FIGURE CAPTIONS**

2 **Figure 1.** Interferon (IFN)- α 2 autoantibody responses in 215 unique participants over 394
3 longitudinal timepoints with convalescent COVID-19. 121 participants experienced post-acute
4 sequelae of SARS-CoV2 infection. Square and triangle data points represent 2 unique
5 individuals that had repeatedly detectable IFN α 2 autoantibodies 41 to 115 days following onset
6 of initial symptoms. Positive controls represents sample from individuals with Autoimmune
7 Polyglandular Syndrome Type ; APS1) and negative control samples are from uninfected
8 individuals. Bars represent mean and standard deviations.

9


10

ACCEPTED MANUSCRIPT

	All Participants	Participants with sampling >60 days following onset of symptoms		IFN-α2 Autoantibody + Participants
		No Long COVID Symptoms	Long COVID Symptoms	
N	215	64	121	2
Age [median (IQR)]	46 (36-55)	48 (39-58)	46 (38-55)	51 (46-56)
Sex at birth [N (%)]				
Female	90 (42)	24 (38)	57 (47)	0 (0)
Male	125 (58)	40 (63)	64 (53)	2 (100)
Race/ethnicity [N (%)]				
Hispanic/Latino	67 (31)	13 (20)	43 (36)	2 (100)
White	106 (49)	33 (52)	62 (51)	0 (0)
Black/African American	11 (5)	4 (6)	6 (5)	0 (0)
Asian	21 (10)	9 (14)	7 (6)	0 (0)
Pacific Islander/Native Hawaiian	4 (2)	3 (5)	1 (1)	0 (0)
Declined to Answer	6 (3)	2 (3)	2 (2)	0 (0)
Hospitalized during acute COVID-19 [N (%)]	48 (22)	14 (22)	29 (24)	2 (100)
Body mass index [N (%)]				
< 25	67 (31)	22 (34)	37 (31)	0 (0)
25 to 30	68 (32)	24 (38)	36 (30)	1 (50)
> 30	77 (36)	17 (27)	48 (40)	1 (50)
Missing	3 (1)	1 (2)	0 (1)	0 (0)
Medical History [N (%)]				
Autoimmune disease	13 (6)	1 (2)	9 (7)	0 (0)
Cancer treated within past 2 years	8 (4)	1 (2)	4 (3)	0 (0)
Diabetes	22 (10)	8 (13)	11 (9)	2 (100)
HIV/AIDS	47 (22)	9 (14)	30 (25)	0 (0)
Heart attack or heart failure	7 (3)	2 (3)	3 (2)	0 (0)
Hypertension or high blood pressure	41 (19)	6 (9)	30 (25)	2 (100)
Lung disease	35 (16)	13 (20)	18 (15)	0 (0)
Kidney disease	4 (2)	1 (2)	2 (2)	0 (0)
Ever smoker [N (%)]	64 (30)	16 (25)	38 (31)	1 (50)
Long COVID with >5 symptoms [N (%)]	-	0 (0)	64 (35.0)	1 (50)
Long COVID with >10 symptoms [N (%)]	-	0 (0)	22 (11.9)	1 (50)

1 **Table 1. Participant demographics, medical history, and COVID-19**
2 **disease course.** Note: Of 215 participants contributing samples, 185 had
3 at least one specimen beyond 60 days from initial infection. This included
4 the 2 IFN antibody positive individuals. 30 individuals had samples
5 available only between 28 and 59 days following infection. Abbreviations:
6 IFN = interferon; IQR = interquartile range.

7
8
9
10



11
12
13

Figure 1
94x100 mm (x DPI)